Experimental evidence indicates that the HDAC6/STAT3 axis regulates PD-L1 expression, suggesting that targeting the MIIP/HDAC6/PD-L1 pathway might enhance immune checkpoint inhibitor efficacy in melanoma [144,145]. Here, MIIP is linked to melanoma.